Biogen announces publication of anti-Lingo-1 study

Biogen Idec has announced the publication of findings from a preclinical study showing that the anti-Lingo-1 antibody can promote spinal cord remyelination and axonal integrity.

The results suggest that the antibody could have a potential role as a treatment for multiple sclerosis (MS) and other demyelinating diseases of the central nervous system (CNS).

Published in the October issue of Nature Medicine, the results confirm previously published data suggesting a role for the anti-Lingo-1 antibody in CNS myelin repair.

Alfred Sandrock, senior vice president for neurology research and development at Biogen, confirmed the encouraging nature of the preliminary findings and highlighted the importance of research into the antibody.

“The anti-LINGO-1 program is a key part of our research and development efforts in MS. We have a diverse pipeline of therapeutic candidates targeting multiple pathways and patient needs with the goal of offering a portfolio of options for people living with this devastating disease.”

Anti-LINGO-1 was discovered by Biogen Idec and is one of several programs in the company’s research and development efforts in MS

Biogen Idec is headquartered in Cambridge, Massachusetts in the US and was formed in 2003 from the merger of two biotechnology companies, Biogen founded in 1978, and IDEC Pharmaceuticals Corporation, founded in 1985.